Regeneron Pharmaceuticals (REGN) lost a patent case with Amgen (AMGN) and now a judge will have to make a decision regarding an injunction on sales of Praluent. Citigroup’s Robyn Karnauskas and Mohit Bansal provide and update:
We spoke to Regeneron regarding the timelines of the injunction decision in the PCSK9 patent case and the company noted that the Judges opinion could come in 3-4 months. The hearing on injunction took place last week and the Judge now will have to form an opinion based on the hearing. This typically takes 3-4 months to get the opinion per the company.
This makes Dupilumab phase 3 data in Atopic Dermatitis next important catalyst. As we noted before, we see $25/sh upside on positive data and $50-$60/sh downside on negative data. Investors are concerned that overhang due to the patent case could limit the upside with Dupilumab phase 3 data. Regeneron has said Dupilumab data would come in 1H16 while Sanofi (SNY) has said SOLO-1/2 data will readout in Q116 while CRONOS will readout in Q216.
Top Heal Care Companies To Watch For 2016: Infinity Pharmaceuticals, Inc.(INFI)
Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies. The company is developing DYNAMO, which is in Phase II study to evaluate the safety and efficacy of IPI-145 dosed at 25 mg; CONTEMPO that is in the Phase Ib/II study of IPI-145 in combination with obinutuzumab or rituximab in patients with untreated follicular lymphoma; BRAVURA, which is in Phase III study to evaluate the safety and efficacy of IPI-145 plus rituximab and bendamustine; and FRESCO that is in Phase II study to evaluate the safety and efficacy of IPI-145 plus rituximab. It is also developing DYNAMO+R, which is in Phase III randomized study to evaluate IPI-145 dosed at 25 mg in c ombination with rituximab, a monoclonal antibody treatment; DUO that is in randomized Phase III monotherapy study evaluating IPI-145 dosed at 25 mg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL); and SYNCHRONY, which is in the Phase Ib study of IPI-145 in combination with obinutuzumab in CLL patients. In addition, the company is conducting a Phase Ib/II trial of IPI-145 in combination with venetoclax, a B-cell lymphoma 2 inhibitor; and developing IPI-549 that is in Phase I study for patients with various solid tumors, including melanoma and non-small cell lung cancer. The company has collaboration and license agreement with AbbVie Inc. to develop and commercialize IPI-145 in oncology; and development and license agreement with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
- [By Lisa Levin]
Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares dropped 70 percent to $1.32. Infinity announced plans to cut 21 percent of the workforce. The company also reported that DYNAMO Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib met its primary endpoint.
Top Heal Care Companies To Watch For 2016: NiSource, Inc(NI)
NiSource Inc., an energy holding company, provides natural gas, electricity, and other products and services in the United States. It operates through two segments, Gas Distribution Operations and Electric Operations. The company provides natural gas service and transportation to residential, commercial, and industrial customers; generates, transmits, and distributes electricity; and provides wholesale and transmission transaction services. It serves approximately 3.4 million natural gas customers and 463,000 electric customers in in Ohio, Pennsylvania, Virginia, Kentucky, Maryland, Indiana, and Massachusetts. The company also owns and operates 3 coal-fired electric generating stations with a net capability of 2,540 megawatts (MW), 3 gas-fired generating units with a net capability of 196 MW, and 2 hydroelectric generating plants with a net capability of 10 MW, as well as a combined cycle gas turbine plant with a capacity of 5 35 MW. The company was formerly known as NIPSCO Industries, Inc. and changed its name to NiSource Inc. in April 1999. NiSource Inc. was founded in 1912 and is headquartered in Merrillville, Indiana.
- [By Lisa Levin]
In trading on Thursday, utilities shares fell by 2.01 percent. Meanwhile, top losers in the sector included Unitil Corporation (NYSE: UTL), down 9 percent, and NiSource Inc. (NYSE: NI), down 5 percent.
Top 10 Net Payout Yield Stocks To Watch Right Now: Take-Two Interactive Software, Inc.(TTWO)
Take-Two Interactive Software, Inc. develops, publishes, and markets interactive entertainment for consumers worldwide. The company offers its products under the Rockstar Games and 2K labels. It develops and publishes action/adventure products under the Grand Theft Auto, Max Payne, Midnight Club, and Red Dead names through developing sequels; offering downloadable episodes, and content and currency; and releasing titles for smartphones and tablets. The company also develops brands in other genres, including the L.A. Noire, Bully, and Manhunt franchises. In addition, it publishes various entertainment properties across platforms and a range of genres, including shooter, action, role-playing, strategy, sports, and family/casual entertainment under the BioShock, Mafia, Sid Meier’s Civilization, and XCOM Enemy Unknown series, as well as Borderlands and Evolve franchises; and various sports simulation titles, including its flagship NBA 2K series, a basketball video game and the WWE 2K series. The companys portfolio of brands also comprise Carnival Games, Rockstar Games Presents Table Tennis, Sid Meier’s Pirates!, Spec Ops, and Top Spin. Its products are designed for console gaming systems, such as Sony’s PlayStation 3 and PlayStation 4, and Microsoft’s Xbox 360 and Xbox One; handheld gaming systems; and personal computers comprising smartphones and tablets. The company delivers its products through physical retail, digital download, online platforms, and cloud streaming services. Take-Two Interactive Software, Inc. was founded in 1993 and is headquartered in New York, New York.
- [By Ahiza Garcia]
The suit against Take-Two Interactive (TTWO) is being brought by Solid Oak Sketches, a group that holds the rights to the tattoos.
Solid Oak Sketches obtained the rights from five tattoo artists by agreeing to pay royalties based on the use of the tattoos, according to the suit.